Home Biosimilar Antibodies Proteases Glutaminase Zampilimab (Anti-TGM2 / Transglutaminase 2)
For research use only. Not for use in humans.

Zampilimab (Anti-TGM2 / Transglutaminase 2)

Synonyms: G-ALPHA-h， GNAH

Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD.

Zampilimab (Anti-TGM2 / Transglutaminase 2)

Quality Control

Batch: Purity: 99% Protein concentration: 3.19mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation glutaminase
6-Diazo-5-oxo-L-norleucine (Diazooxonorleucine) 10
GK921 3
UPGL00004 0
BPTES 59
Telaglenastat (CB-839) 113
Sirpiglenastat (DRP-104) 0
Glutaminase C-IN-1 0
IACS-6274 0
JHU395 0
JHU-083 4
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD.
References

Product Details

CAS No. 2098280-42-1
Isotype Human IgG4SP
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07516951 RECRUITING Drug: CHF10067|Drug: CHF10067 Idiopathic Pulmonary Fibrosis Chiesi Farmaceutici S.p.A. 2026-07-08 PHASE2
NCT04335578 TERMINATED Drug: Zampilimab|Drug: Placebo Chronic Allograft Injury UCB Biopharma SRL 2019-10-21 PHASE1; PHASE2
NCT04705350 COMPLETED Drug: Zampilimab|Drug: Placebo Healthy Study Participants UCB Biopharma SRL 2021-01-11 PHASE1
NCT02879877 COMPLETED Drug: UCB7858|Drug: Placebo Healthy Volunteers UCB Biopharma S.P.R.L. 2016-07-11 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-09-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.